October 22, 2021

Alvotech USA Inc. et al v. Abbvie Inc et al

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. March 09, 2022

    Alvotech, AbbVie Deal Allows For Humira Biosimilar In 2023

    Icelandic biopharmaceutical firm Alvotech has settled an intellectual property fight with AbbVie Inc. over Alvotech's proposed biosimilar version of AbbVie's blockbuster drug Humira, which is used to treat arthritis and other conditions.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS